{"protocolSection": {"identificationModule": {"nctId": "NCT00739596", "orgStudyIdInfo": {"id": "CSPP100AUS03"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans", "officialTitle": "An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension", "acronym": "ATLAAST"}, "statusModule": {"statusVerifiedDate": "2011-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-07"}, "primaryCompletionDateStruct": {"date": "2009-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-08-21", "studyFirstSubmitQcDate": "2008-08-21", "studyFirstPostDateStruct": {"date": "2008-08-22", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-14", "resultsFirstSubmitQcDate": "2010-12-14", "resultsFirstPostDateStruct": {"date": "2011-01-12", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-09-20", "lastUpdatePostDateStruct": {"date": "2016-10-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension", "African American", "aliskiren", "hydrochlorothiazide", "systolic blood pressure", "diastolic blood pressure", "amlodipine", "stage 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 332, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren Hydrochlorothiazide (HCTZ)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks"]}, {"label": "Amlodipine", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Amlodipine: 8 weeks"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks", "description": "Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks", "armGroupLabels": ["Aliskiren Hydrochlorothiazide (HCTZ)"]}, {"type": "DRUG", "name": "Amlodipine: 8 weeks", "description": "Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks", "armGroupLabels": ["Amlodipine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment", "description": "To assess the change from baseline in MSSBP after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension.", "timeFrame": "Baseline and 8 weeks"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure (MSDBP) After 8 Weeks of Treatment", "description": "To assess the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension.", "timeFrame": "Baseline and 8 weeks"}, {"measure": "Change in Mean Sitting Pulse Pressure (MSPP) After 8 Weeks of Treatment", "description": "To compare the change from baseline in mean sitting pulse pressure (MSPP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension.", "timeFrame": "Baseline and 8 weeks"}, {"measure": "Percentage of Responders After 8 Weeks of Treatment.", "description": "To compare the percentage of responders after 8 weeks of treatment with an aliskiren HCTZ based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension: \\[ Responders were defined as patients with MSSBP \\< 140 mm Hg or a decrease from baseline \u2265 20 mm Hg at 1st response. A response was counted when a patient first achieved MSSBP \\< 140 mm Hg or a decrease from baseline \u2265 20 mm Hg.\\]", "timeFrame": "8 weeks"}, {"measure": "Percentage of Participants Achieving BP Control After 8 Weeks of Treatment", "description": "To compare the percentage of patients achieving BP control (\\<140/90 mm Hg) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension.", "timeFrame": "8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed.\n* Men or women 18 years and older of African American background; self identified\n* Patients with stage 2 hypertension. Patients must have a MSSBP \u2265 160 mmHg and \\< 200 mmHg at Visit 5 (randomization)\n\nExclusion Criteria:\n\n* Office blood pressure measured by cuff (MSSBP \u2265 200 mmHg and/or MSDBP \u2265 110 mmHg) at any visit.\n* Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives whichever is longer.\n* History of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class (CCBs or thiazide diuretics) as the study drugs.\n* Long QT syndrome or QTc \\> 450 msec for males and \\> 470 msec for females at screening.\n* History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.\n* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\\> 5 mIU/mL)\n* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method.\n\n  1. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent. Reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation.\n  2. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels \\> 40 mIU/mL \\[and estradiol \\< 20 pg/mL\\] or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.\n* History or evidence of a secondary form of hypertension.\n* Known Keith-Wagener Grade III or IV hypertensive retinopathy.\n* History of cerebrovascular accident, transient ischemic cerebral attack (TIA), heart failure (NYHA Class II-IV), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI) in the last 12 months.\n* Current angina pectoris requiring pharmacological therapy.\n* Other protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Sites in USA", "city": "East Hanover", "state": "New Jersey", "country": "United States", "geoPoint": {"lat": 40.8201, "lon": -74.36487}}]}, "referencesModule": {"references": [{"pmid": "21545398", "type": "DERIVED", "citation": "Ferdinand KC, Pool J, Weitzman R, Purkayastha D, Townsend R. Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. J Clin Hypertens (Greenwich). 2011 May;13(5):366-75. doi: 10.1111/j.1751-7176.2010.00416.x. Epub 2011 Jan 18."}], "seeAlsoLinks": [{"label": "Related Info", "url": "http://www.bloodpressureresearch.com"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aliskiren Hydrochlorothiazide (HCTZ)", "description": "Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks"}, {"id": "FG001", "title": "Amlodipine", "description": "Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "166"}, {"groupId": "FG001", "numSubjects": "166"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "141"}, {"groupId": "FG001", "numSubjects": "149"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "17"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Unsatisfactory Therapeutic Effect", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Patient Withdrew Consent", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks"}, {"id": "BG001", "title": "Amlodipine", "description": "Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "166"}, {"groupId": "BG001", "value": "166"}, {"groupId": "BG002", "value": "332"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "141"}, {"groupId": "BG001", "value": "143"}, {"groupId": "BG002", "value": "284"}]}]}, {"title": "\u2265 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "48"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52.0", "spread": "11.27"}, {"groupId": "BG001", "value": "53.1", "spread": "11.56"}, {"groupId": "BG002", "value": "52.6", "spread": "11.41"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "91"}, {"groupId": "BG002", "value": "176"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "75"}, {"groupId": "BG002", "value": "156"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment", "description": "To assess the change from baseline in MSSBP after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension.", "populationDescription": "The intent-to-treat (ITT) population consisted of all randomized patients who received at least one dose of study medication and had at least one valid post-baseline assessment of the primary efficacy variable. Last observation carried forward (LOCF) method was used for replacing missing values with post-baseline assessments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "162"}, {"groupId": "OG001", "value": "162"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "168.2", "spread": "8.49"}, {"groupId": "OG001", "value": "168.1", "spread": "7.99"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "138.8", "spread": "18.21"}, {"groupId": "OG001", "value": "139.1", "spread": "14.45"}]}]}, {"title": "Change from baseline to Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-29.4", "spread": "17.95"}, {"groupId": "OG001", "value": "-29.0", "spread": "13.17"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (MSDBP) After 8 Weeks of Treatment", "description": "To assess the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension.", "populationDescription": "The intent-to-treat (ITT) population consisted of all randomized patients who received at least one dose of study medication and had at least one valid post-baseline assessment of the primary efficacy variable. Last observation carried forward (LOCF) method was used for replacing missing values with post-baseline assessments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "162"}, {"groupId": "OG001", "value": "162"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "96.0", "spread": "9.76"}, {"groupId": "OG001", "value": "95.0", "spread": "8.86"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "86.0", "spread": "12.02"}, {"groupId": "OG001", "value": "84.0", "spread": "9.72"}]}]}, {"title": "Change from Baseline to Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.0", "spread": "11.08"}, {"groupId": "OG001", "value": "-11.0", "spread": "9.81"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Pulse Pressure (MSPP) After 8 Weeks of Treatment", "description": "To compare the change from baseline in mean sitting pulse pressure (MSPP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension.", "populationDescription": "The intent-to-treat (ITT) population consisted of all randomized patients who received at least one dose of study medication and had at least one valid post-baseline assessment of the primary efficacy variable. Last observation carried forward (LOCF) method was used for replacing missing values with post-baseline assessments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "162"}, {"groupId": "OG001", "value": "162"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "72.2", "spread": "12.10"}, {"groupId": "OG001", "value": "73.1", "spread": "11.59"}]}]}, {"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "52.7", "spread": "14.91"}, {"groupId": "OG001", "value": "55.1", "spread": "12.13"}]}]}, {"title": "Change from Baseline to Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.4", "spread": "13.73"}, {"groupId": "OG001", "value": "-18.0", "spread": "11.20"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Responders After 8 Weeks of Treatment.", "description": "To compare the percentage of responders after 8 weeks of treatment with an aliskiren HCTZ based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension: \\[ Responders were defined as patients with MSSBP \\< 140 mm Hg or a decrease from baseline \u2265 20 mm Hg at 1st response. A response was counted when a patient first achieved MSSBP \\< 140 mm Hg or a decrease from baseline \u2265 20 mm Hg.\\]", "populationDescription": "The intent-to-treat (ITT) population consisted of all randomized patients who received at least one dose of study medication and had at least one valid post-baseline assessment of the primary efficacy variable.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Cumulative percentage of responders", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "162"}, {"groupId": "OG001", "value": "162"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "84.6", "lowerLimit": "-13.92", "upperLimit": "1.58"}, {"groupId": "OG001", "value": "90.7", "lowerLimit": "13.92", "upperLimit": "1.58"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving BP Control After 8 Weeks of Treatment", "description": "To compare the percentage of patients achieving BP control (\\<140/90 mm Hg) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension.", "populationDescription": "The intent-to-treat (ITT) population consisted of all randomized patients who received at least one dose of study medication and had at least one valid post-baseline assessment of the primary efficacy variable.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Cumulative percentage of participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks"}, {"id": "OG001", "title": "Amlodipine", "description": "Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "162"}, {"groupId": "OG001", "value": "162"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "63.6", "lowerLimit": "-9.90", "upperLimit": "12.37"}, {"groupId": "OG001", "value": "62.3", "lowerLimit": "-9.90", "upperLimit": "12.37"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "8 Weeks", "eventGroups": [{"id": "EG000", "title": "Aliskiren HCTZ", "description": "Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks.", "seriousNumAffected": 5, "seriousNumAtRisk": 166, "otherNumAffected": 0, "otherNumAtRisk": 166}, {"id": "EG001", "title": "Amlodipine", "description": "Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks.", "seriousNumAffected": 3, "seriousNumAtRisk": 166, "otherNumAffected": 0, "otherNumAtRisk": 166}], "seriousEvents": [{"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 166}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 166}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 166}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 166}]}, {"term": "Encephalitis herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 166}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 166}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 166}]}, {"term": "Rhabdomyolysis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 166}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 166}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}